IL270285B2 - Diagnostic advanced glycation end-product antibodies - Google Patents

Diagnostic advanced glycation end-product antibodies

Info

Publication number
IL270285B2
IL270285B2 IL270285A IL27028519A IL270285B2 IL 270285 B2 IL270285 B2 IL 270285B2 IL 270285 A IL270285 A IL 270285A IL 27028519 A IL27028519 A IL 27028519A IL 270285 B2 IL270285 B2 IL 270285B2
Authority
IL
Israel
Prior art keywords
age
cells
sample
patient
disease
Prior art date
Application number
IL270285A
Other languages
English (en)
Hebrew (he)
Other versions
IL270285B1 (en
IL270285A (en
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corp filed Critical Siwa Corp
Publication of IL270285A publication Critical patent/IL270285A/en
Publication of IL270285B1 publication Critical patent/IL270285B1/en
Publication of IL270285B2 publication Critical patent/IL270285B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
IL270285A 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies IL270285B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501424P 2017-05-04 2017-05-04
US201762610003P 2017-12-22 2017-12-22
PCT/US2018/030931 WO2018204679A1 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Publications (3)

Publication Number Publication Date
IL270285A IL270285A (en) 2019-12-31
IL270285B1 IL270285B1 (en) 2025-02-01
IL270285B2 true IL270285B2 (en) 2025-06-01

Family

ID=62223287

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270285A IL270285B2 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Country Status (9)

Country Link
US (1) US20200150131A1 (https=)
EP (1) EP3619540A1 (https=)
JP (2) JP2020521117A (https=)
KR (2) KR20200003067A (https=)
CN (1) CN110832327A (https=)
AU (1) AU2018261622A1 (https=)
CA (1) CA3062082A1 (https=)
IL (1) IL270285B2 (https=)
WO (1) WO2018204679A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3826670A1 (en) * 2018-07-23 2021-06-02 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
US20220396841A1 (en) * 2019-12-02 2022-12-15 Viome Life Sciences, Inc. Detection and elimination of aberrant cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
US20230181730A1 (en) 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
AU2021326232A1 (en) * 2020-08-11 2023-04-13 Shenzhen Protgen Ltd. Young and undamaged human serum albumin improves longevity of human
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
JP7607149B2 (ja) * 2021-04-09 2024-12-26 カチョン ユニバーシティ オブ インダストリー－アカデミック コーオペレイション ファウンデイション グリコトキシン、グリコトキシンに結合した特定タンパク質、またはグリコトキシン－特定タンパク質複合体を含む神経変性疾患のバイオマーカー
EP4388016A1 (en) 2021-08-20 2024-06-26 Siwa Corporation Methods and compositions for treating fibrotic diseases
CN114624362A (zh) * 2022-03-17 2022-06-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种检测血清中晚期糖基化终末产物的试剂盒及其应用
CN118562721A (zh) * 2024-06-27 2024-08-30 广州市华代生物科技有限公司 一种基于全皮模型的糖化衰老模型及抗糖效果测试评价方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702704A (en) * 1991-12-20 1997-12-30 The Rockefeller University Antibodies to in vivo advanced glycosylation endproducts
WO2010005531A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
WO2012047629A2 (en) * 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
JP4012722B2 (ja) * 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
EP2582293B1 (en) * 2010-06-18 2016-04-20 DiagnOptics Holding B.V. Method and apparatus for determining an autofluorescence value of skin tissue.
IL286427B2 (en) * 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
JP2017527580A (ja) * 2014-09-12 2017-09-21 ザ プロクター アンド ギャンブル カンパニー 老化防止スキンケア組成物及びレジメン
US10358502B2 (en) * 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702704A (en) * 1991-12-20 1997-12-30 The Rockefeller University Antibodies to in vivo advanced glycosylation endproducts
WO2010005531A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
WO2012047629A2 (en) * 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL270285B1 (en) 2025-02-01
WO2018204679A1 (en) 2018-11-08
EP3619540A1 (en) 2020-03-11
KR20200003067A (ko) 2020-01-08
RU2019139256A3 (https=) 2022-01-18
IL270285A (en) 2019-12-31
US20200150131A1 (en) 2020-05-14
CA3062082A1 (en) 2018-11-08
AU2018261622A1 (en) 2019-12-12
KR20240006702A (ko) 2024-01-15
CN110832327A (zh) 2020-02-21
JP2023098996A (ja) 2023-07-11
JP2020521117A (ja) 2020-07-16
RU2019139256A (ru) 2021-06-07

Similar Documents

Publication Publication Date Title
IL270285B2 (en) Diagnostic advanced glycation end-product antibodies
IL261006A (en) Method and preparation for the treatment of cancer, killing of metastatic cancer cells and prevention of cancer metastases using an antibody to advanced glycation end products
US20210253739A1 (en) Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells
IL281714B2 (en) Methods for increasing the effectiveness of FOLR1 cancer therapy
EP3742167A1 (en) Composition for screening ongoing progress of alzheimer's disease by using beta amyloid oligomer in nasal discharge specimen and method for screening ongoing progress of alzheimer's disease by using same
JP6890581B2 (ja) Ｃｄ３７の検出のための抗体およびアッセイ
IL292176A (en) Humanized antibody and method for using it
Del Giudice et al. Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work?
Yu et al. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety
Wang et al. Autoantibodies to BACE1 promote Aβ accumulation and neurodegeneration in Alzheimer’s disease
JP2023553247A (ja) がん診断のための組成物および方法
RU2788905C2 (ru) Диагностические антитела к конечным продуктам глубокого гликирования
EP4610657A1 (en) Diagnosis of immune-mediated inflammatory diseases using mmp12 as indicator, and medicine for treating immune-mediated inflammatory diseases via mmp12 inhibition
Li et al. Acid sphingomyelinase-ceramide induced vascular injury determines colorectal cancer stem cell fate
JP7762937B2 (ja) 膵臓がんの診断補助方法及び膵臓がん治療用医薬組成物
US12459998B2 (en) Alpha-synuclein binding antibodies, or antigen binding portions thereof
HK40081546A (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK40029952B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK1256931B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
Lu Developing blood-based biomarkers of disease progression in Amyotrophic Lateral Sclerosis